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1. Introduction 
Age-related neurodegenerative diseases are recognized as a major health issue worldwide. 
Due to our aging society, the number of people suffering from dementia is drastically 
increasing, creating serious challenges for society and the public health system. Our current 
paucity of effective treatments and total lack of cures, when coupled with this increasing 
prevalence, makes the exploration of novel strategies for therapeutic interventions of the 
utmost importance. Although many of the disease-causing proteins have been identified, the 
molecular mechanisms that underlie disease pathogenesis are still not fully understood. One 
common feature of neurodegenerative diseases is the accumulation of misfolded proteins 
into toxic oligomers and aggregates. Gaining extensive knowledge regarding the formation 
of these cytotoxic species, the cellular machineries that guarantee their persistence or 
clearance and the basis of their toxicity is essential for the development of both preventive 
and therapeutic interventions. A powerful approach to increase our knowledge on these 
disease processes is the use of proteomic tools to define the interaction networks of disease-
related proteins. Significant technical progress has been made in the last decade that now 
allows high-throughput screening for protein-protein interactions on a proteome level. In 
this book chapter, we review the diverse proteomic approaches that have been used to 
define the interactomes of disease-linked proteins and the impact of these findings on the 
understanding of pathogenic processes.  
1.1 Cellular mechanisms of neurodegeneration 
The intracellular and extracellular aggregation of mutated and/or misfolded proteins into 
highly ordered β-sheet rich aggregates, termed amyloid, is a common hallmark of many 
neurodegenerative diseases such as Alzheimer’s (AD), Parkinson’s (PD) and Huntington’s 
(HD) disease (Fig.1).  
AD is the most common progressive neurodegenerative disease, affecting millions of people 
worldwide. AD patients show neuronal loss, the deposition of extracellular amyloid plaques 
consisting of amyloid β peptides (Aβ, (Aβ40 and Aβ42)) and intracellular neurofibrillary 
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tangles consisting of hyperphosphorylated and cleaved Tau. Although various models have 
been proposed to explain the pathogenic processes underlying the disease, the exact 
mechanisms leading to AD are not fully understood (Mudher & Lovestone, 2002).  
The amyloid cascade hypothesis proposes that aberrant cleavage of the amyloid precursor 
protein (APP) by two different proteases (β/γ-secretases) leads to the accumulation of 
aggregation-prone Aβ peptides that eventually cause disease through multiple mechanisms, 
including microglial infiltration, generation of reactive oxygen species and synaptic damage 
(Hardy & Selkoe, 2002). According to this model, early intracellular Aβ accumulation 
induces the aggregation of the microtubule associated protein Tau. In familial forms of AD, 
genetic mutations within the APP or γ-sectretase cause extensive formation of Aβ 
protofibrils, which leads to neurotoxicity.  
The Tau or tangle hypothesis, however, claims that it is the disruption of microtubule 
binding and aggregation of Tau by phosphorylation or genetic mutations that initiates the 
disease cascade (Maccioni et al., 2010). The formation of neurofibrillary tangles subsequently 
leads to disintegration of the neuronal cytoskeleton, which causes the disruption of neuronal 
transport and cell death. 
Although Tau and Aβ became the focus of extensive research, the exact disease mechanisms 
remain unclear. The complexity of the disease is reflected in the fact that many other 
susceptibility genes or proteins involved in development and progression of this disease 
have been identified in the last decade.  
After AD, PD represents the second most prevalent neurodegenerative disease. It is 
characterized by the loss of dopaminergic neurons in the substantia nigra and formation of 
intracellular inclusions (Lewy bodies) consisting of α-synuclein, a presynaptic protein of 
unknown function (Martin, I. et al., 2011). Importantly, in idiopathic Parkinson’s disease, α-
synuclein inclusions first localize to defined brain areas and pathology appears to progress in a 
topographically predictable manner (Braak et al., 2004). The majority of cases are sporadic and 
age-related. However the identification of several mutated genes in the small number of early 
onset familial forms of PD implicate various proteins contributing to disease progression. So 
far, genetic mutations in α-synuclein (SNCA), parkin (PARK2), ubiquitin carboxyl-terminal 
esterase L1 (UCHL1), parkinson protein 7 (PARK7, DJ-1), PTEN-induced putative kinase 1 
(PINK1), leucine-rich repeat kinase 2 (LRRK2), α-synuclein interacting protein (SNCAIP) and 
glucosidase, beta, acid (GBA) have been linked to familial forms of PD (Martin, I. et al., 2011).  
Polyglutamine expansions within unrelated proteins are the underlying cause of nine 
different neurodegenerative pathologies, including HD, spinobulbar muscular atrophy and 
spinocerebellar ataxias (SCAs) (Hands & Wyttenbach, 2010). HD, a dominantly inherited 
neurodegenerative disease that is caused by an expansion of the polyglutamine tract in the 
Huntingtin (HTT) protein, is the most widely studied of these diseases. It manifests in 
movement disorder, psychological disturbances and cognitive dysfunction. Hallmarks of 
HD are cytoplasmic and nuclear inclusions that consist of N-terminal fragments of 
expanded HTT. Mutant HTT causes cellular dysfunction and neurodegeneration, probably 
through a combination of toxic gain-of-function and loss-of-function mechanisms. Many 
proteins have been found to localize to HTT inclusions and it has been postulated that 
mutant HTT interferes with the function of a diverse variety of cellular proteins, leading to 
toxic alterations of many pathways.  
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Although the disease-related proteins in AD, PD and HD have different identities, common 
cellular mechanisms underlie the formation of oligomeric complexes and amyloidogenic 
aggregates. Whether neurotoxicity is caused by a toxic loss-of-function of the disease-
associated proteins or a toxic gain-of-function of the built up amyloids is still under debate. 
Gaining more insights into the cellular and molecular pathways leading to aggregation and 
neurotoxicity could, thus, help to identify general and specific targets for therapeutic 
intervention in a variety of neurodegenerative diseases.  
1.2 Protein aggregation and neurotoxicity 
Maintaining the functionality of the proteome in a highly dynamic cellular environment 
constantly exposed to physical, metabolic and environmental stresses is essential for cell 
survival. Protein homeostasis, or “proteostasis”, is controlled by a highly interconnected 
network of different protein quality control pathways that balance protein folding, 
degradation and aggregation (Kettern et al., 2010). Molecular chaperones are central players in 
this network. According to the current concept of chaperone function, chaperones act as 
surveillance factors that scan the cell and recognize non-native proteins. Upon binding to a 
substrate protein, they prevent its aggregation by facilitating folding or disposal through the 
proteasomal (CAP – chaperone assisted proteasomal degradation) or autophagic (CMA – 
chaperone mediated autophagy, CASA – chaperone assisted selective autophagy) machineries. 
The association of regulatory cochaperones determines the function of the chaperone as a 
“folding” or “degradation” factor. Inefficient or unsuccessful folding of a substrate protein 
thereby enhances the probability that degradation-inducing cochaperones will associate and 
initiate ubiquitination of the client protein. The different protein quality control pathways do 
not operate independently from each other and their coordinated action allows the cell to 
adjust to different alterations that endanger the integrity of the proteome. 
Aggregation of disease-linked proteins probably represents a second line of defense against 
cytotoxic effects of misfolded proteins. At this stage, aggregate formation is probably a 
cytoprotective mechanism by which the cell sequesters misfolded proteins or oligomers that 
cannot be degraded by the proteasome. It has been shown that aggregate formation is not an 
uncontrolled process, but can be defined as part of the cellular protein quality control 
(Tyedmers et al., 2010). Usually, protein aggregates can be cleared by macroautophagy 
(Martinez-Vicente & Cuervo, 2007). However, this second line of defense is also overtaxed in 
neurodegenerative diseases, as the enhanced production of misfolded proteins is  cumulative. 
Thus, the continuous presence of large or numerous aggregates at later disease stages probably 
exerts a negative effect on many cellular functions and enhances toxicity. The inhibition of cell 
function may be due to either sterical hindrance of cellular processes, such as axonal transport, 
or to coaggregation of other proteins that are then depleted from the cell (Olzscha et al., 2011). 
Taken together, understanding the mechanisms that lead to aggregation of disease-linked 
proteins is crucial for the identification of processes that cause toxicity in neurodegeneration.  
Sporadic neurodegenerative diseases are usually age-related and reflect the overtaxing of a 
large variety of cellular processes that normally control protein homeostasis (Douglas & 
Dillin, 2011). In contrast hereditary early-onset dementias are caused by a set of genetic 
mutations that lead to the constant production of misfolded and aggregation-prone proteins. 
Mutations causing familial neurodegenerative diseases have been shown to increase the 
aggregation tendency of several disease-associated proteins in different ways.  
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Fig. 1. Protein aggregation in neurodegenerative disease. To be functional, a protein has to 
fold into an appropriate three-dimensional structure. Aggregation of unfolded cellular 
proteins is usually prevented by the quality control machinery, which supports the folding 
process and ensures the removal of unfolded or misfolded proteins. Mutations that enhance 
the tendency of disease-linked proteins to aggregate, overexpression of aggregation-prone 
proteins or proteotoxic stress during aging may, however, overwhelm the cellular folding 
and degradation machineries. Once the quality control machinery is overwhelmed, protein 
aggregation may be a second line of defense to prevent cytotoxic effects of misfolded 
proteins or prefibrillary aggregates. Most of the disease-linked proteins in 
neurodegenerative diseases form highly ordered β-sheet-rich amyloid fibrils. The continued 
production of aggregation-prone proteins concomitant with decreased protein degradation 
leads to increased aggregation, likely leading to toxicity at later stages. 
Often, mutations in the coding sequence of the disease-causing gene affect the propensity of 
the protein to misfold and, eventually, aggregate. In HD and several spinocerebellar ataxias 
(SCAs), a clear correlation between the lengths of the polyglutamine stretch in the disease-
causing proteins and the tendency to aggregate has been observed (Martindale et al., 1998). 
Furthermore, three missense mutations in the α-synuclein gene that are associated with 
early-onset forms of PD (A30P, E46K and A53T) have been found to enhance the propensity 
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of α-synuclein to aggregate (Li et al., 2001, Greenbaum et al., 2005). Several mutations in Tau 
have been linked to various neurodegenerative diseases; while Tau mutations affect 
different aspects of the protein’s function, all result in increased aggregation (Wolfe, 2009).  
Importantly, altered gene dosage is sometimes sufficient to cause disease. A genomic 
duplication or triplication involving the α-synuclein locus has been found to cause some 
forms of familial early-onset PD (Chartier-Harlin et al., 2004, Singleton et al., 2003). In 
addition, the higher risk for dementias with neuropathological features of AD in Down’s 
syndrome has been attributed to the triplication of the APP gene in these patients (Rumble 
et al., 1989).  
Mutations can, however, also alter posttranslational modifications of the disease-causing 
proteins. Proteolytic cleavage of disease-related proteins often precedes amyloid deposition 
and mutations in the coding region can also affect proteolytic processing of the disease-
related protein. Generation of the neurotoxic Aβ peptide by β- and γ-secretase mediated 
sequential proteolysis of APP plays a central role in AD (O’ Brien & Wong, 2011). Pathogenic 
APP mutations that cause early-onset familial AD are clustered around the α-, β-, γ-secretase 
cleavage sites and affect the ratio of Aβ40/42, the latter having an increased propensity to 
form amyloid plaques (van Dam & De Deyn, 2006). The role of proteolytic cleavage of Tau 
in neurodegeneration is less well understood, but proteolysis of Tau can be clearly linked to 
aggregation and neurotoxicity (Wang et al., 2010). Proteolytic cleavage of several 
polyglutamine disease-linked proteins liberates toxic protein fragments that can form 
aggregates (Shao & Diamond, 2007). Finally, hyperphosphorylation of Tau and 
phosphorylation of α-synuclein and ataxin-1 has been shown to enhance their aggregation. 
Recently, other posttranslational modifications such as oxidation, sumoylation, 
ubiquitination or nitration have also been implicated in the aggregation of Tau, α-synuclein 
and polyglutamine-rich proteins (Beyer, 2006, Martin, L. et al., 2011, Pennuto et al., 2009). In 
addition, glycosylation affects the processing of APP (Georgopoulou et al., 2001).  
2. Interactome mapping in diseases 
In the last decades, significant progress has been made uncovering a large number of 
genetic mutations that are associated with a variety of genetically inherited disorders, 
summarized in the Online Mendelian Inheritance in Man database (OMIM) (Amberger et 
al., 2011). Clinical symptomatology, however, is less dependent on single mutations than on 
how whole organisms and systems are altered. 
The pathology of one single gene mutation mapped to a specific disease is rarely caused by 
the malfunction of just one mutated gene product, but rather reflects perturbations of the 
whole interaction network in which the altered protein is embedded. This concept is in line 
with the finding that cellular proteins linked to the same disease exhibit a high tendency to 
interact with each other (Barabasi et al., 2011). In the interactome, the corresponding disease 
module, thus, consists of a group of proteins that function together in a cellular pathway or 
process whose breakdown results in a specific pathophenotype. To understand local 
network perturbations underlying the diseases phenotype, it is necessary to systematically 
explore the complex interaction network in which the disease-associated proteins are 
interconnected. Systems-based approaches to human diseases can, thus, lead to the 
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identification of new disease genes and pathways. As drug discovery starts to concentrate 
on network-based targets rather than single gene targets, a deeper understanding of the 
disease module is crucial for the development of treatments (Morphy & Rankovic, 2007). 
Moreover the identification of disease modules can help to uncover subnetworks of 
interacting proteins that are shared between diseases with similar pathologies, such as 
neurodegeneration. A powerful approach to detect disease modules in neurodegenerative 
diseases is the interactome mapping of the different disease-linked proteins in combination 
with the generation of a complete map of the human interactome. The integration of the 
interactome of a diseases module with gene expression data or structural proteomic data 
will significantly advance our understanding of the pathophysiology of the disease in search 
for effective treatments.  
2.1 The human interactome 
To date, most attempts to map protein-protein interaction networks have been made using 
model organisms such as the yeast Saccharomyces cerevisiae, the nematode Caenorhabditis 
elegans and the fruitfly Drosophila melanogaster. This model organism usage is due to the 
better and earlier annotation of their genomes. In the last decade, several attempts to map 
the human interactome have been made, representing a first crucial step towards the 
understanding of cellular interconnectivity and the identification of networks that play a 
key role in human diseases (Vidal et al., 2011). In addition, the combination of high-
throughput datasets and literature-based protein-protein interactions into databases helped 
to extend existing interactome maps and made information obtained from high-throughput 
screens more accessible (Tab. 1). 
 
Database Description Webadress 
 
BioGRID 
 
Biological General Repository for Interaction 
Datasets 
http://thebiogrid.org/ 
BIND 
 
 
 
Biomolecular Interaction Network Database: 
component database of BOND (Biomolecular 
Object Network Databank) 
integrates a range of component databases 
including Genbank and BIND, the 
Biomolecular Interaction Network 
Database, resource for cross database 
searches  
http://bond. 
unleashedinformatics. 
Com/ 
DIP 
 
Database of Interacting Proteins 
 
http://dip.doe-
mbi.ucla.edu/dip/ 
Main.cgi 
GWIDD Genome Wide Docking Database: 
integrated resource for structural studies of 
protein-protein interactions on genome-
wide scale 
http://gwidd. 
bioinformatics.ku.edu/ 
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Database Description Webadress 
 
Human 
Protein 
Inter-
action 
Database 
interactions of HIV-1 proteins with host cell 
proteins, other HIV-1 proteins, or proteins 
from disease organisms associated with 
HIV / AIDS 
http://www.ncbi.nlm.nih. 
gov/RefSeq/ 
HIVInteractions/index.html 
HPID Human Protein Interaction Database  
 
http://wilab.inha.ac. 
kr/hpid/ 
HPRD 
 
 
Human Protein Reference Database: 
integrates information on domain 
architecture, post-translational 
modifications, interaction networks and 
disease association for each protein in the 
human proteome 
http://www.hprd.org/ 
HUGE ppi Human Unidentified Gene-Encoded large 
proteins 
http://www.kazusa.or.jp/h
uge/ppi/ 
IBIS 
 
Inferred Biomolecular Interactions Server http://www.ncbi.nlm.nih.g
ov/Structure/ibis/ibis.cgi 
IntAct 
 
curated from published protein-protein 
interaction data 
 
http://www.ebi.ac.uk/ 
intact/ 
MINT Molecular Interaction Database 
 
http://mint.bio.uniroma2.it
/mint/Welcome. 
do 
MIPS 
 
Mammalian Protein-Protein Interaction 
Database 
 
http://mips.helmholtz-
muenchen.de/proj/ 
ppi/ 
NetPro 
 
Comprehensive database of protein-protein 
and protein-small molecules interaction 
 
http://www.molecularconn
ections.com/home/en/hom
e/products/NetPro 
POINeT prediction of the human protein-protein 
interactome based on available orthologous 
interactome datasets 
http://point.bioinformatics.t
w/main.do?file= 
architecture.txt&selectMenu
=environment.ini 
Table 1. A selection of protein-protein interaction databases.  
In the past years, improvement of techniques for high-throughput interaction screening 
has helped to generate high-quality protein interaction data for many organisms, 
including humans. In addition, an empirical framework has been proposed to evaluate 
the quality of data generated by high-throughput mapping approaches and to estimate 
the size of interactome networks (Venkatesan et al., 2009). Based on empirical sizing, the 
authors predict the human interactome to consist of ∼130,000 interactions. Previous 
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estimates of human interactome size range from 150,000 – 650,000 interactions 
(Venkatesan et al., 2009). To date ∼23000 human protein-protein interactions have been 
reported. With the authors’ estimation that 42% of these reported interactions represent 
true positives, only ∼8% of the full interactome size has been identified so far (Venkatesan 
et al., 2009). Comprehensive mapping of the human interactome will require further 
development of complementary, systematic, unbiased and cost-effective high-throughput 
mapping approaches.  
2.2 Experimental strategies for mapping protein-protein interactions 
A large variety of experimental and computational methods can be used to identify protein-
protein interactions. Two complementary methods are primarily applied for the large-scale 
mapping of protein-protein interactions. Mapping of binary interactions was first 
accomplished by a high-throughput adaption of the yeast two-hybrid (Y2H) system, 
originally developed by Fields and Song (Fields & Song, 1989). Mapping of indirect protein 
associations within protein complexes can be carried out by a combination of affinity 
purification and mass spectrometry (AP/MS) (Rigaut et al., 1999). Unfortunately both 
techniques have their limitations in terms of quality and coverage. Quality assessment of 
datasets from different interaction studies has shown that Y2H and AP/MS data provide the 
same quality but represent different subpopulations of the interactome, resulting in 
networks with different topologies and biological functions (Seebacher & Gavin, 2011). 
Binary maps from Y2H screens were enriched for transient signalling interactions and 
interactions between different protein complexes, whereas data generated from AP/MS 
experiments preferentially detected interaction within a protein complex. The combinatorial 
application of both techniques is, therefore, recommended to obtain more complete protein 
interaction maps. The lack of a complete interactome map can be overcome to a certain 
extent by using data-mining strategies to identify sub-networks from different incomplete 
interactome maps.  
2.3 The yeast two-hybrid system (Y2H) 
Originally developed by Field and Song (Field & Song, 1989) to detect the interactions of 
two proteins, Y2H has been further adapted to high-throughput screening (Koegl & Uetz, 
2007). The Y2H is based on the finding that many transcription factors can be divided into a 
DNA-binding domain (BD) and an activation domain (AD) that maintain their functionality 
when separated and recombined. In the two-hybrid approach the BD (e.g. from the yeast 
Gal4 or the E. coli LexA protein) is fused to a protein of interest to generate the bait (Fig. 2A). 
The prey is constructed by the fusion of the AD (e.g. from the yeast Gal4 or the heterologous 
B42 peptide) with a set of open reading frames (ORFs). Bait and prey fusions are then 
coexpressed in yeast. When the bait and prey proteins interact, a functional transcription 
factor is reconstituted. Reconstitution of the transcription factor is detected by measuring 
the activity of a reporter gene. Several reporter genes have been used so far. In the “classic” 
two-hybrid, auxotrophic markers such as HIS3 and LEU2 allow selection by growth on 
selective media lacking histidine or leucine. Another commonly used reporter is the 
bacterial β-galactosidase. Recently, GFP has been successfully used as a reporter gene and 
many others are under investigation. Although Y2H has proved valuable in the 
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confirmation and identification of many protein-protein interactions, there are experimental 
limitations of this system. 
 
Fig. 2. The yeast two-hybrid system and high-throughput adaptions.  
A Principle of the yeast two-hybrid system. To test for a direct interaction, proteins X and 
Y are coexpressed as fusions with the binding domain (BD), or bait, and the activation 
domain (AD), or prey, of a transcription factor (e.g. Gal4) in yeast. If protein X and Y 
interact directly a functional transcription factor is reconstituted which induces 
transcription of a reporter gene that allows detection of X-Y interaction (e.g. GFP) or 
selection for X-Y interaction (e.g. HIS3).  
B Workflow of the matrix or array approach for high-throughput interaction screening. A 
prey array is generated by dispensing yeast clones that each express a different AD fusion in 
a multiwell plate. In an automated step, the prey array is then pinned on a multiwell plate 
containing yeast clones that express the bait (BD fusion). Prey and bait clones are allowed to 
mate and diploids are selected based on the expression of selection genes. If the bait and 
prey proteins interact directly, then the expression of a reporter gene that allows screening 
for interactors of the bait protein is induced.  
C Principle of the exhaustive or random library screen for high-throughput screening. In 
this screen, a bait fusion is screened against a pooled prey library consisting of ORFs or ORF 
fragments. Diploids and positive interactors are selected based on growth of selection plates. 
In contrast to the array approach each positive clone has to be picked and sequenced after 
selection to identify the prey protein.  
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To obtain worthwhile Y2H results, the bait and prey fusion proteins must properly fold and 
not be hindered from proper interaction. Their interaction must be stable and not require 
posttranslational modification. Furthermore, the interaction in the Y2H takes place in the 
nucleus, though this restriction can be circumvented by the use of protein fragments that 
fold more efficiently and are able to translocate to the nucleus. AD and BD fusions alone can 
also sometimes auto-activate reporter gene expression. This is excluded by performing a 
self-activation assay of the bait and prey constructs. In this test, a control plasmid coding for 
an unrelated BD or AD fusion-protein is added along with the construct of interest. The 
auto-activation background of a HIS3 reporter can be reduced by the addition of the HIS3 
inhibitor, 3-AT. The usage of the opposite fusion construct or a different protein fragment is 
also often effective in suppressing auto-activation. In addition, several alternative genetic 
screening techniques have been developed to allow the detection of interactions for 
transcription activators and membrane proteins (Auerbach et al., 2002). 
2.3.1 Large-scale yeast two-hybrid screens 
The most powerful application of the Y2H system, one that can generate comprehensive 
protein-protein interaction maps, is the unbiased screening of whole libraries. Two 
adaptions of the “classical” Y2H for high-throughput screening are the “matrix approach“ 
or “array approach” and the “exhaustive library screening” or “random library screening” 
approach (Fig. 2B and 2C) (Koegl & Uetz, 2007).  
In the array approach, a set of defined prey proteins is tested for interaction with a bait 
protein (Fig. 2B). Bait and prey constructs are individually transformed into isogenic 
reporter strains of opposite mating types. Yeast clones expressing a single AD fusion are 
dispensed into single wells of a multi-well plate, generating a matrix of AD fusions. The 
array of AD fusions is then spotted onto another multi-well plate containing one yeast clone 
expressing a single BD fusion for mating. In this way, all BD fusions are mated to AD arrays. 
A positive interaction is then detected by the ability of a diploid cell to activate the reporter 
gene (e.g. growth on selective media). As multiple assays can be performed with the same 
system under identical conditions, they can later be compared. To exclude false positives, 
experiments are usually performed in duplicates and only interactions found in both 
experiments are considered to be true. As whole genomes are available as ordered clone 
sets, each component of the array has a known identity and no sequencing is required after 
identifying a positive interaction. To accelerate the screening procedure, a pooling strategy 
can be applied. In the pooled array screen, AD fusions of known identity are tested as pools 
of AD fusions against the BD strains. This means that the identification of interaction 
partners from a positive pool requires retesting of all members. It is also possible to use 
pools of baits against an AD array. 
A second approach to analyse the interactome of whole proteomes is the “exhaustive library 
screening” or “random library screening” approach (Fig. 2C). In this assay, a BD fusion is 
screened against a library of AD fusions of full Length ORFs or ORF fragments. For this 
approach, it is not necessary to know the sequence of the whole genome, as random prey 
libraries can be generated from randomly cut genomic DNA. In addition a large number of 
cDNA libraries is commercially available. Like the array screen, the bait and prey constructs 
are individually transferred into isogenic yeast strains of opposing mating types. However, 
in contrast to the matrix approach, the different AD fusions are not separated on an array. 
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Instead each BD fusion strain is mated with pooled AD fusion strains. After mating of the 
two strains, the diploid yeast cells are plated on selective media to screen for interactions. 
The identity of the AD fusion has to be determined by yeast colony PCR of positive colonies 
followed by sequencing.  
In terms of quality assessment, rigorous evaluation and filtering of the raw data will 
enhance the quality and reliability of results. Routine testing of positive interactions is 
performed in duplicate and protein interactions that are not reproducible are discarded. 
From interactome studies, it is estimated that the coverage of array-based two-hybrid 
screens is only ∼20% (Rajagopala et al., 2011). This high false negative rate is probably 
caused by the technical limitations of the system. Furthermore, different attempts to map 
the yeast interactome show very little overlap with each other and with annotated 
protein-protein interactions, probably due to the usage of different Y2H systems (Uetz et 
al., 2000, Ito et al., 2001). Recent attempts to generate a high quality dataset of the yeast 
interactome have revealed over 1000 new interactions (Yu et al., 2008). Further technical 
development and improvement is needed to increase the coverage of interactome screens. 
However, as the Y2H only covers a subset of interactions, a complementary AP/MS 
approach is necessary to generate a comprehensive map of the interactome (Yu et al., 
2008). 
2.4 Affinity purification coupled to mass spectrometry 
Most proteins function in cellular processes as multi-subunit protein complexes. A well-
established method to identify protein co-complexes is based on affinity purification 
followed by mass spectrometry (Fig.3) (Bauer & Kuster, 2003). The classical 
coimmunoprecipitation protocol is commonly used to detect whether two proteins interact 
in cellular systems, but can be also used to identify new interaction partners. In this 
approach, one protein is affinity captured along with its associated proteins by a specific 
antibody immobilized on Protein A or G sepharose. Experimental details like the affinity 
tag, lysis conditions, incubation time and washing conditions have a significant impact on 
the output and need to be optimized depending on the protein complex stability and 
localization. To preserve protein-protein interactions and native conformations, relatively 
mild conditions should be used during lysis. TritonX-100 or NP-40 are widely used in cell 
lysis buffers as non-ionic detergents and efficiently lyse membranes but are mild enough to 
preserve protein-protein interactions. Other variables that can influence the outcome of the 
affinity purification are salt concentrations, divalent cation concentrations and pH. The 
purified complex is rinsed several times to remove unspecifically bound proteins and 
complexes are eluted from the resin by low or high pH, high salt concentrations, by 
competition with a counter ligand or by adding Laemmli buffer to the beads. After 
purification, the isolated protein complex is usually separated on 1D or 2 D gels and protein 
lanes or spots are digested by trypsin and subsequently analyzed by mass spectrometry. It is 
also possible to precipitate eluted protein complexes and trypsinize the pellet. Comparison 
of the proteins detected in the sample with a negative control leads to the identification of 
specific interaction partners. Although low background binding is favoured, the stringency 
of washing steps needs to be adjusted to preserve more dynamic or transient interactions. 
Nonspecific binding can be reduced by adding low levels of detergent or by adjusting the 
salt concentration.  
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Fig. 3. Workflow of AP/MS for high throughput screening. Cells that express an epitope-
tagged form of the protein of interest are lysed to extract protein complexes. The protein 
complexes are then isolated using a tag- specific antibody. The antibody-bound protein 
complex is immobilized on Protein A or Protein G sepharose and non-specific interactors 
are eliminated by several wash steps. As a control, the immobilized antibody is incubated 
with an untagged cell extract or a cell extract containing a tagged control protein (e.g. GFP).  
After purification, the protein complexes can be either separated on a gel or eluted and 
precipitated. The gel slices or the protein pellet are then digested to generate peptide 
fragments that can be analyzed by mass spectrometry to identify co-complexed proteins.  
2.4.1 Large scale AP/MS screens 
Proteome wide interaction studies need to meet certain criteria, such as reproducibility and 
low background binding. To circumvent the need of a specific antibody, the bait protein can 
be fused to an epitope tag that allows the pull down of different protein complexes using the 
same antibody under standardized conditions. A large variety of different epitopes has been 
used in the past and are commercially available (e.g. HA, FLAG, MYC). One disadvantage 
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of this technique, however, is that the epitope-tagged proteins are overexpressed in the cell. 
Cytotoxicity induced by overexpression can be prevented by the usage of inducible 
expression systems. The tag might also interfere with protein folding and localization. 
Despite these limitations, coimmunoprecipitation via an epitope tag has been successfully 
used in proteome wide screens (Gavin et al., 2002, Ho et al., 2002). 
Another coimmunoprecipitation protocol that is frequently used for high-throughput 
experiments is the tandem affinity purification (TAP) developed by Rigaut (Rigaut et al., 
1999). The basic concept is similar to the coimmunoprecipitation of epitope tagged proteins. 
The main difference, however, is the use of two tags. One commonly used TAP tag consists 
of an IgG binding protein (Protein A) linked to a calmodulin-binding domain (CBD) via a 
TEV protease recognition site. Protein complexes are purified by the incubation of lysates 
with IgG sepharose beads that capture the Protein A tag. After washing the immobilized 
complex is eluted by TEV cleavage. Eluted protein can then be bound to a calmodulin 
sepharose column via their CBD domain. As the binding to calmodulin is calcium 
dependent, immobilized protein complexes can be eluted by addition of EDTA. The major 
advantage of this technique over one-step purification is increased specificity, reducing 
background binding to levels suitable for large-scale analysis (Gavin et al., 2002, Krogan et 
al., 2006). However, the long purification protocol preserves only stable interactions. For this 
reason, one-step purification with an epitope-tagged protein of interest is preferable if a 
broader range of interactions should be captured. Although the stringency of the 
purification protocol needs to be adjusted, the high sensitivity of mass spectrometry 
requires a minimum of non-specific binding to avoid laborious post-experimental filtering, 
especially in the case of large-scale experiments. An alternative approach to eliminate non-
specific interactors without loosing low abundant or transiently interacting proteins is the 
use of quantitative mass spectrometry (Kaake et al., 2010).  
The analysis of the isolated protein complex typically starts from separation of the complex 
components on 1D SDS-PAGE gels based on their molecular weight or 2D gels based on 
their charge and molecular weight followed by protease digestion. Usually, trypsin or Lys-C 
are employed to cleave the protein in peptide fragments because they generate peptides that 
have basic amino acids at their C-termini, which is favourable for detection and sequencing 
by mass spectrometry. In large-scale experiments, however, all purified proteins are 
precipitated and digested together to avoid time-consuming separation steps by gel 
electrophoresis and instead protein samples are fractionated by liquid chromatography (LC) 
after tryptic digest. Depending on the complexity of the sample, different approaches for 
protein identification by mass spectrometry can be used (Bauer and Kuster 2003). Complex 
peptide mixtures are analyzed by liquid chromatography in combination with tandem mass 
spectrometry (LC-MS/MS), whereas protein samples that have been separated on 1D SDS-
PAGE or 2D gels and have therefore a lower complexity are analyzed by peptide mass 
fingerprinting (PMF).   
PMF is an analytical method in which the absolute masses of peptides from a tryptic digest 
can be measured by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF). The measured masses of the sample are then looked up in a 
database that contains predicted peptide masses that have been generated by in silico digests 
for every protein. The results are statistically analyzed to find a significant overlap between 
the experimentally generated and predicted peptide masses. The identification method is 
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based on the assumption that it is very unlikely that the exact same combination of peptide 
masses is found in more than one protein. Although this method can be applied to protein 
mixtures, the presence of different proteins complicates the analysis. Therefore, PMF is 
usually applied to identify proteins or protein mixtures isolated from 1 or 2D gels. Mixtures 
of more than five proteins require the additional use of tandem mass spectrometry for 
reliable protein identification. 
Tandem mass spectrometry, uses a combination of sequence and mass information for the 
identification of proteins (MS/MS). In a first step, the masses of peptides from the tryptic 
digest are measured. Single peptides are then isolated from the mixture in the mass 
spectrometer and collided with inert gas molecules, which leads to fragmentation of the 
peptide backbone. Peptide fragments generated by this method differ in length by one 
amino acid. Measurement in the mass spectrometer allows determination of mass 
differences between two adjacent fragments that indicate a particular amino acid residue. 
The peptide mass, fragment mass and sequence is then compared against one or more 
databases to identify the proteins in the sample. Each peptide is individually identified and 
attributed to a protein in the mixture. For the analysis of complex samples, tandem mass 
spectrometry is generally combined with liquid chromatography to fractionate the peptide 
mixture before analysis by tandem mass spectrometry (LC-MS/MS).   
Due to the sensitivity of the method and depending on the stringency of the purification 
protocol, post-experimental filtering is necessary to eliminate non-specific interactors. The 
ultimate goal of post-experimental analysis is the maximum reduction of false positives 
while maintaining the maximum coverage. Usually proteins that coimmunoprecipitate 
with a protein of interest are compared to proteins that are detected in a control sample to 
define unspecific interactions. Each of the experiments is commonly done at least in 
duplicate to identify high confidence interacting proteins. Whereas reproducibility seems 
to be a good indicator for true positive interactions, the quality assessment by 
comparisons with existing datasets depends on the selected gold standard. An ideal gold 
standard reference data set would be confirmed by other sources and should be generated 
by a comparable method to that being applied. Yu et al. (Yu et al., 2008) used an approach 
in which they tested several reference databases using various techniques to select a good 
gold standard.  
2.5 Quality assessment of interactome mapping datasets 
The identification of disease-modules and the interactome mapping of disease-linked 
proteins relies on the quality of the available reference datasets and the filtering of the 
experimentally generated interaction data. In early studies the precision of interactome 
maps was estimated by the integration of other biological attributes, such as gene 
ontology, or comparison with literature curated datasets. However, these methods suffer 
limitations in the estimation of data quality, as they need to be complete and unbiased. 
Recent efforts to establish an empirical framework for protein interaction maps will 
improve the estimation of accuracy and sensitivity for interaction maps generated by 
high-throughput interaction screens (Venkatesan et al., 2009). This empirical framework 
evaluates four different quality parameters of the currently used methods to estimate 
quality:  
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1. Screening completeness: the fraction of overall possible ORF pairs that are tested to 
generate the interaction map.  
2. Assay sensitivity: the fraction of all interactions that could be identified by the applied 
experimental method.  
3. Sampling sensitivity: the fraction of all detectable interactions that are identified in one 
trial of an assay under specific experimental conditions.  
4. Precision: the fraction of known true positive pairs in the dataset.  
Estimation of these parameters offers a quantitative idea of the coverage and accuracy of an 
interaction map and, when used in a standardized way, enables the comparison of different 
datasets.  
3. Interactome mapping of disease-linked proteins in neurodegenerative 
diseases 
Although great efforts have been made to uncover specific and shared pathways underlying 
neurodegeneration, many cellular mechanisms involved remain to be uncovered. As many 
disease-linked proteins function in multisubunit complexes and are functionally embedded 
in large cellular networks, gaining extensive knowledge of the architecture and composition 
of these complexes and networks is crucial to identify disease-linked pathways and to 
establish new disease markers. Based on this knowledge, diagnosis of early-onset dementias 
could be significantly improved and new therapeutic strategies could be developed. For 
age-related dementias, the discovery and characterization of shared pathways could pave 
the way towards common therapeutic interventions. To uncover the networks and 
complexes in which disease-linked proteins are embedded, interaction studies of many 
disease linked proteins, such as AD–associated (Chen et al., 2006, Krauthammer et al., 2004, 
Liu et al., 2006, Norstrom et al., 2010, Perreau et al., 2010, Soler-Lopez et a., 2010, Tamayev et 
al., 2009), PD-associated (Engelender et al., 1999, Meixner et al., 2011, Schnack et al., 2008, 
Suzuki, 2006, Woods et al., 2007, Zheng et al., 2008), HD-associated (Goehler et al., 2004, 
Kaltenbach et al., 2007) and ataxia-associated proteins (Kahle et al., 2011, Lim et al., 2006) as 
well as of prion protein (PrP) (Nieznanski, 2010) have been conducted. In addition, an 
interactome study that utilizes artificially designed amyloid-like fibrils has been performed 
and focused more on the general mechanisms underlying the toxic gain-of-function of β-
sheet rich proteins (Olzscha et al., 2011).  
3.1 Interactome mapping of disease- linked genes by large-scale Y2H 
Several Y2H studies have been conducted to identify interaction partners of disease-related 
proteins in neurodegenerative diseases. In the following section, we highlight several 
studies that have contributed significant insight into disease networks by using new 
approaches or developing new ideas.  
3.1.1 Generating the AD interaction network 
An interesting approach to generate a complete interaction map for AD has been 
employed by Soler-Lopez et al. (Soler-Lopez et al., 2010). The authors elegantly combined 
different strategies to establish the most complete AD interaction network to date by 
exploring the interactomes of all known AD-linked proteins. The integration of their data 
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with literature-based information provides new insights into the molecular interplay of 
different functional modules within the AD network and has helped to identify new 
candidate genes. Whereas most of the other interactome mapping approaches only 
focused on one prominent disease-linked protein, this study underlines the need to study 
the complete set of disease-associated genes in order to get the whole picture of a complex 
disorder like AD.  
Although extensively studied, the cellular mechanisms that underlie the neurophathological 
changes associated with AD remain elusive. Despite the central role of APP and Tau, AD is 
a genetically complex disease and several genetic risk factors have been identified in the last 
decades. As it has been shown that the susceptibility/causative genes for many diseases are 
often interconnected within the same biological module, Soler-Lopez et al. applied different 
network biology strategies in their recently published study to build the most complete AD 
related interactome (Soler-Lopez et al., 2010).  
The authors used available information from the Online Mendelian Inheritance in Man 
database to assemble a set of 12 well established AD related genes that they termed “seed”. 
To be classified as a seed gene at least one mutation of the gene must be associated with AD 
in the OMIM Morbid Map. Interestingly, quantification of the degree of connectivity by 
computing the minimal path length between seed genes shows that the seed genes are 
connected by three links on average, whereas control sets (randomly picked genes and 
randomly picked disease causing genes from different disorders) were connected by more 
then four links on average. Starting from their defined AD seed genes, the authors 
developed a strategy to discover new disease genes. For this purpose they aimed to identify 
proteins that match at least one of the following criteria: 1.) the encoded proteins must 
directly interact with the seed genes, 2.) the gene must locate to a known genetic 
susceptibility locus and 3.) the gene must have altered expression in AD.   
To define the interaction network of their selected seed proteins, they performed Y2H 
interaction screens. Baits were constructed for nine genes from the seed (three ORFs were 
not available) and yeast clones for the individual baits were transformed with an adult brain 
cDNA prey library. Each experiment was done in five replicates. 72 positive interactions 
resulted from this screen and were retested by pairwise cotransformant Y2H arrays. 32 high 
confidence interactors for the seed proteins could be validated.  
In a second approach, the authors performed a pairwise candidate screen based on 
published genome wide association studies that identified four chromosomal regions (7q36, 
10q24, 19q13.2, 20p) containing unknown AD susceptibility genes. They focused on 185 
genes that are located in chromosomal regions linked to AD. Of those, 44 candidate genes 
known to be coexpressed with AD genes and suitable for Y2H screening were tested for 
their interaction with the 9 seed proteins. A systematic matrix-based Y2H was performed to 
identify interactors of the AD seed among the candidates extracted from the AD linked 
chromosomal regions. Two different technical approaches, a mating and a cotransformation 
screen, were used to perform the Y2H. With the identified interactions from the two Y2H, 
the authors generated a high-confidence interaction core (HC). The interactors identified in 
the library screen had to be validated to be included in the HC and the interactors from the 
pairwise candidate screen had to activate at least two reporter genes to be defined as high-
confidence interaction. The final HC contained 8 seed genes (no HC interactors were 
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identified for one seed gene) and 66 interactors, 27 from the library screen and a further 39 
from the pairwise candidate screen. Interestingly, the different interactor set showed no 
overlap and only a low overlap with other studies, highlighting the importance of utilizing 
multiple approaches to increase coverage. 
The HC interactions were validated by complementary strategies, such as GST pull down 
assays, coimmunoprecipitations and colocalization studies. Due to the high stringency 
applied for the identification of HC interactors, 87% of the interactors could be validated. 
The analysis of the HC identified four novel direct interactions between well-established AD 
related proteins (APP, A2M, APOE, PSEN1, PSEN2), implicating a possible link between 
plaque formation and inflammatory processes and providing insights into the regulation of 
APP cleavage. The assembled network showed an enrichment of 3 biological processes 
(oxidation reduction, regulation of apoptosis and negative regulation of cell motion), 5 
molecular functions (protein binding, mono-oxygenase activity, oxygen binding, actin 
binding and integrin binding) and 6 cellular compartment terms (cytoplasm, 
pseudopodium, platelet alpha granule lumen, cytosol, cytoskeleton and internal side of 
plasma membrane) as well as altered expression of 17 out of 66 interactors, based on 
microarray data (Blalock et al., 2004). Furthermore, 6 out of 58 direct interactors were listed 
in the AlzGene database, whereas none of the non-interacting proteins were found in the 
database. Network analysis suggests a role for the programmed cell death 4 protein 
(PDCD4) in regulating neuronal death. PCDC4 was found to bind to the seed proteins 
PSEN2 and APOE and is located in a functionally homogenous network module enriched 
for translational elongation. As PCDC4 is upregulated in AD brain tissue, the authors 
suggest that the protein plays a role in Aβ toxicity. Another interesting member in the AD 
interactome network (AD-PIN) is ESCIT (evolutionary conserved signalling intermediate in 
Toll pathway), which links the redox signalling and immune response modules. Based on 
published data, the authors hypothesize that ESCIT may represent a molecular link between 
mitochondrial processes and AD lesions. Taken together, newly identified genes in the HC 
are likely related to AD onset or progression.  
To generate a complete AD-PIN, the interaction partners of the HC were retrieved from 
literature-curated databases. The AD-PIN was then used to identify functional modules 
within the network that help to link processes potentially involved in AD and to identify the 
relationship between new candidate genes.    
Taken together, this integrative approach combined stringent interaction screening and 
extensive validation by complementary strategies to build a comprehensive disease 
interaction map and highlight the importance of a network view of disease and the necessity 
of data integration from different sources when exploring disease interactomes. 
3.1.2 The ataxia-ome 
Disorders having a common clinical presentation likely also have common altered 
pathways. Examples of such diseases are familial spinocerebellar ataxias. A multitude of 
disease-associated mutations have been discovered, each leading to gain or loss of normal 
protein function. These mutations all inevitably lead to loss of Purkinje cells through an as 
yet unknown common pathway. An interesting study by Lim et al. used an Y2H approach 
to explore the interaction network of 54 proteins involved in 23 ataxias (Lim et al., 2006). 
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This study nicely showed that interactome mapping of different disease related genes can 
help to identify common pathways shared by diseases with similar presentation, such as 
neurodegenerative disorders. 
Similar to the AD interactome study, the authors first defined a set of 23 ataxia-causing 
genes (11 recessive and 12 dominant, including the polyglutamine-mediated SCAs) whose 
mutations are linked to ataxias in humans or mice. Paralogs and an additional 31 directly 
interacting proteins were grouped together as ataxia-associated proteins. Bait and prey 
constructs for each of the genes were constructed to perform matrix-based mating type 
reciprocal screens against the human ORFeome. To minimize false positives, they used a 
stringent version of the Y2H system that expresses fusion proteins at low levels. Yeast clones 
containing single ataxia baits were mated with yeast clones of the opposite mating type 
containing 188 different ORF minilibrary pools (Rual et al., 2005). In a second screen, 
reciprocal interactions were tested between human ORFeome baits and ataxia preys to 
exclude effects caused by misfolding of the fusion protein and to include autoactivation 
baits. The overlap of the two screens comprises only 5.2% of the observed interactions, 
which is typical for reciprocal studies (Rual et al., 2005). To include a tissue specific library, 
the authors screened a human brain cDNA library using the same experimental setup. 29 
interactions were overlapping in both screens, indicating that screening different types of 
libraries can enhance the coverage of the interactome map, as splice forms of a single gene 
are often spread across cDNA libraries. 83% of the interactions were validated 
experimentally by GST pull down assays from HEK293 cells with randomly picked 
interaction pairs. Analysis of the interaction sets found that 72% of those with compartment 
annotations colocalize together and 98% of the interactors share a GO branch, 
demonstrating the high quality of the Y2H generated interaction network. 
A large interconnected network between the 36 ataxia genes and 541 preys was revealed for 
ataxia processes. In addition, 13 ataxia causing baits were linked directly or through 
common interacting proteins, indicating that the proteins in this interconnected network are 
functionally linked.  
To build the ataxia network, Y2H data were integrated with interaction data from available 
databases. The network was then divided into a direct ataxia network, which contains first-
order protein interactions, and the expanded ataxia network, which contains additional 
second- or third-order interactions. Further comparison of this ataxia network with 
networks generated from unrelated disease proteins showed that ataxia network nodes have 
a shorter path length, with a higher number of single hub interconnections. Surprisingly, 18 
out of 23 ataxia causing proteins interacted directly or indirectly.   
The ataxia interactome assembled by Lim et al. shows that for different ataxias, the similar 
pathophenotype is indeed caused by the alteration of shared pathways and processes. 
Main hubs in this ataxia network are involved in DNA repair and maintenance, 
transcription, RNA processing and protein quality control. Taken together, this kind of 
approach shows that genes and proteins that are involved in the same or related disorders 
are highly interconnected, often operating in the same pathways. In this way, interactome 
studies can prove valuable in identifying the shared pathways underlying related 
phenotypes. 
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3.2 Interactome mapping of disease-linked genes by AP/MS 
Several AP/MS approaches have been successfully applied to identify interaction partners 
of disease-linked proteins in different neurodegenerative diseases. The following section 
summarizes two quantitative approaches that aim to identify distinct disease-relevant 
interaction networks. 
3.2.1 QUICK screen to identify a PD-associated interaction network 
Although PD represents a complex disorder for which several genetic risk factors have been 
identified, no complementary PD network has yet been generated, unlike for AD (Soler-Lopez 
et al., 2010). To explore the physiological function of the disease associated leucine-rich repeat 
kinase 2 (LRRK2), Meixner et al. used a new AP/MS protocol to identify the interaction 
network under stoichiometric constraints, called QUICK (quantitative immunoprecipitation 
combined with knockdown) (Meixner et al., 2011, Selbach & Mann, 2006). The QUICK screen 
aims to detect protein-protein interactions at endogenous levels and in their normal cellular 
environment by using a combination of SILAC, RNA interference, coimmunoprecititation and 
quantitative MS. For the QUICK approach, NIH3T3 cells were transduced with a lentiviral 
shRNA construct to knock down endogenous LRRK2. WT and LRRK2 knock down cells were 
then grown in SILAC medium containing either normal heavy isotope labeled lysine or 
arginine. For coimmunoprecipitation, an LRRK2 specific antibody was crosslinked to Protein 
G sepharose. Cells were lysed in buffer containing 1% NP-40 and phosphatase inhibitors. 
Equal numbers of heavy and light SILAC labeled cells were incubated with LRRK2 sepharose 
and then pooled. Purified LRRK2 complexes were eluted after several washing steps in 
Laemmli buffer. Separation of the proteins was achieved by SDS-PAGE gel electrophoresis, 
followed by tryptic digestion of gel slices. Interaction partners were identified by subsequent 
LC-MS/MS. Identified interaction partners were verified using the same approach, without 
prior SILAC labeling. Using this protocol, 36 proteins were identified as high confidence 
LRRK2 interactors. Bioinformatic analysis and integration of interaction data from different 
databases showed that these proteins are mainly members of the actin family and actin-
associated proteins, pointing to an important role for LRRK2 in actin cytoskeleton based 
processes. Additional experiments demonstrated that LRRK2 binds to F-Actin in vitro and 
regulates its assembly. Knockdown of LRRK2 leads to morphological alterations and 
shortened neurite processes in primary neurons, further indicating a physiological role for 
LRRK2 in cytoskeletal organization. As the experimental strategy of the QUICK approach 
aims to identify interactors at physiological conditions (endogenous expression of the target 
protein) with specific antibodies, this method is well suited to explore the physiological 
function of other disease-linked proteins. Moreover, using knock-down or knock-out cells for 
control immunoprecipitations with a specific antibody proved as a suitable control. So far, this 
approach is not suited for large-scale applications involving several candidate proteins, but is 
of interest for generating interactome maps for one protein.  
3.2.2 Interactome mapping of amyloid-like aggregates 
Ordered proteinacious aggregates with high ß-sheet content, termed amyloid, are a 
characteristic of many neurodegenerative diseases. Whether this aggregation is cytoprotective 
or cytotoxic is still under debate. One hypothesis for aggregate toxicity is that these aggregates 
sequester cellular proteins, thereby leading to functional impairment (Chiti & Dobson, 2006). 
www.intechopen.com
 
Protein Interactions 
 
234 
To uncover the gain-of-function toxicity of amyloid-like fibrils in general, Olzscha et al. 
defined the interactome of artificial β-sheet proteins designed to form amyloids (West et al., 
1999). The advantage of this method is that none of the artificial proteins have endogenous 
interaction partners, which allows for the identification of common amyloid interacting 
proteins independent of the identity of the aggregating protein. β4, 17 and 23, which differ in 
their β-sheet propensity, with β23 having the highest tendency to form β-sheets, were selected 
for interactome mapping. As a control, the authors used an α-helical protein with a similar 
amino acid composition (α-S284). Interaction analysis of the different β-sheet proteins was 
performed using SILAC followed by LC-MS/MS. Constructs coding for MYC-labelled 
proteins were transfected into HEK293 cells and proteins were labelled with light, medium or 
heavy arginine and lysine isotopes. Different experimental setups were chosen: (1) empty 
MYC tag vector, MYC α-S284, MYC β23; (2) MYC α-S284, MYC β4, MYC β17; (3) MYC β4, 
MYC β17, MYC β23 for quantitative MS. Lysates from heavy, medium and light labelled cells 
were mixed in a 1:1:1 ratio and amyloidogenic aggregates were isolated using anti-MYC 
coupled magnetic beads to avoid loss of the protein aggregates due to centrifugation. After 
purification the bound proteins were eluted and processed for LC-MS/MS analysis. 
Experiments were performed in triplicate. Proteins were defined as interactors if they were 
enriched relative to the α-S284 control or one of the β proteins with >95% confidence in two of 
the three repeats. Interactors were validated by coimmunoprecipitation and western blotting 
or immunofluorescence analysis. Bioinformatic analysis of the amyloid interactomes revealed 
that aggregates sequester a large amount of large, unstructured proteins that occupy essential 
hub position in housekeeping functions such as transcription and translation, chromatin 
regulation, vesicular transport, cell motility and morphology, as well as protein quality 
control. The authors hypothesize that amyloidogenic aggregation coaggregates a metastable 
subproteome, thereby causing perturbations in essential cellular networks leading to toxicity. 
3.3 Interactome mapping by combinatorial approaches: The HD interactome 
As Y2H and AP/MS approaches identify different groups of interactors, the combination of 
the two experimental strategies may prove valuable for the generation of comprehensive 
interaction maps of disease-linked proteins. In a study on HD, Kaltenbach et al. used these 
two approaches to generate a comprehensive HD interactome, which was then tested for 
modulators of polyglutamine toxicity. Importantly, the two approaches revealed distinct but 
biologically relevant interactions (Kaltenbach et al., 2007).  
In this study the authors performed Y2H and AP/MS approaches in parallel to generate a 
comprehensive HTT interactome. Assuming that HTT and its interactors are functionally 
linked and regulate each other, the HTT interactome should be enriched for genetic 
modifiers of neurotoxicity. To test this hypothesis, the authors generated a Drosophila model 
of polyglutamine toxicity. For the AP/MS, different recombinant TAP-tagged HTT fragment 
baits were constructed (HTT 1-90: Q23, Q48, Q75; HTT 443-1100 and HTT-2758-3114) and 
purified from bacteria for pull down assays with mouse or human brain tissue and mouse 
muscle tissue. Purified complexes were then analyzed by MS. HTT fragments 1-90 were also 
used to probe HeLa, HEK293 and M17 neuroblastoma cell lysates. The interaction lists from 
the different pull downs were filtered by excluding proteins observed in a control pull down 
with the TAP tag alone and subjected to statistical analysis. The interaction lists were 
compared to a database of high-scoring peptides from 88 other unrelated pull downs. By 
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using this approach, the authors generated a list of 145 mouse and human specific 
interactors with WT and expanded HTT fragments. In a complementary assay, a set of 
additional HTT interactors was identified by Y2H with HTT fragment baits (WT: 23Q and 
mutant: >45Q) against prey libraries from 17 different human tissue cDNA sources. Again, 
only baits generated from N-terminal fragments gave reproducible results. Filtering of the 
data was performed to generate a high confidence interaction dataset. Only interactions that 
were observed at least three times in the Y2H were integrated into the dataset; interactors 
were further compared to a database of Y2H interaction screens such that promiscuous 
interactors could be excluded. Finally, all positive prey constructs were retested by 
cotransformation into yeast strains expressing bait constructs. Previously published HTT 
interactors were included regardless of whether they matched the quality assessment 
criteria. A total of 104 interactors were identified by this Y2H approach.  
The interactome was tested for possible genetic interaction in a fly model of polyglutamine 
toxicity. In this model, the N-terminal fragment of human HTT cDNA, including a 128Q 
expansion in exon 1, is expressed in the eye. The resulting neurodegenerative phenotype is 
visible by examining the retinal histology. Interactors that have orthologues in the fly and 
for which suitable fly stocks for overexpression or partial loss-of-function were available 
were selected from both high-confidence datasets. 60 interactors divided equally between 
interactors from the Y2H and AP/MS approach were tested as modifiers of polyglutamine 
mediated toxicity. 80% of the tested interactors altered the readout of more than one allele in 
a single background or a single allele in multiple backgrounds. The high confidence 
interaction dataset was further validated by coimmunoprecipitation studies using lysates 
from WT and HD mice. Data from this study strongly suggest that Y2H and AP/MS are of 
comparable quality in identifying biologically relevant interactions. Gene ontology analysis 
demonstrated that modifiers cluster into different groups, such as cytoskeletal organization, 
signal transduction, synaptic transmission, proteolysis and regulation of transcription and 
translation. Based on their experimentally generated interaction datasets, the authors built 
an interaction map of HD by integrating interaction data from different databases.  
Interacting proteins of the HD network that were confirmed as modifiers in the fly model 
were shown to have diverse biological functions, such as synaptic transmission, cytoskeletal 
organization, signal transduction and transcription. In addition the authors revealed an 
unknown association between the HTT fragment and components of the vesicle secretion 
apparatus, suggesting that modulation of SNARE-mediated neurotransmitter secretion may 
be a physiological function of HTT. The involvement of HTT in these processes suggests a 
model in which mutant HTT interferes with different cellular pathways, leading to 
pathology. 
4. Summary 
Proteins do not operate alone, but instead function as a large interconnected network. 
Disease-related mutations, consequently, disrupt not only the function of individual 
proteins, but also the larger network in which these proteins function, only thereby 
leading to clinically relevant pathology. While many complex diseases are caused by an 
array of mutations in any of a multitude of genes, these all lead to a similar pathology. 
Focusing not just on individual proteins but, rather, on the network of proteins altered in 
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diseases will prove essential to both identifying new candidate genes for this and related 
disease, as well as to provide new targets for the development of therapeutic 
interventions. A combination of different experimental and bioinformatic approaches has 
proved valuable in the network analysis of neurodegenerative diseases. Further studies 
are necessary to generate high quality, comprehensive datasets, which can be used to 
identify shared disease pathways. 
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